A review of the safety and efficacy of nebivolol in the mildly hypertensive patient

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 909-917

  Cockcroft, John ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Arterial stiffness; Beta blocker; Heart failure; Hypertension; Nebivolol; Nitric oxide

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN; ARGININE; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; LIPID; LIPOPROTEIN; LOSARTAN; METOPROLOL; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PERINDOPRIL; PLACEBO; TRIACYLGLYCEROL;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ARTERY COMPLIANCE; ARTERY DISEASE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART EJECTION FRACTION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ARTERIES; BENZOPYRANS; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HEART FAILURE; HUMANS; HYPERTENSION; NITRIC OXIDE;

EID: 38149040832     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Benetos A, Rudnichi A, Safar M, et al. 1998. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension, 32:560-4.
2. Benetos A, Safar M, Rudnichi A, et al. 1997. Pulse pressure:a predictor of long-term cardiovascular mortality in a French male population. Hypertension, 30:1410-5.
3. Blacher J, Guerin AP, Pannier B, et al. 1999. Impact of aortic stiffness on survival in end-stage renal disease. Circulation, 99:2434-9.
4. Blacher J, Staessen J, Girerd X, et al. 2000. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Int Med, 160:1085-9.
5. Bonapace S, Rossi A, Cicoira M, et al. 2003. Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathy. Circulation, 107:1603-8.
6. Boutouyrie P, Tropeano AI, Asmar R, et al. 2002. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. Hypertension, 39:10-5.
7. Bowman AJ, Chen CP-H, Ford GA. 1994. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol, 38:199-204.
8. Breithaupt-Grogler K, Leschinger M, Belz GG, Butzer R, Erb K, de Mey C, and Sinn W. 1996. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc Drugs Ther, 10:49-57.
9. Brunner H, Cockcroft JR, Deanfield J, et al. 2005. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens, 23:233-46.
10. Carlberg B, Samuelsson O, Lindholm LH. 2004. Atenolol in hypertension: is it a wise choice? Lancet, 364:1684-9.
11. Chen CP-H, Ting C-T, Lin S-J, et al. 1995. Different effects of fosinipril and atenolol on wave reflection in hypertensive patients. Hypertension, 25:1034-41.
12. Cleophas TJ, Agrawal R, Lichtenthal A, et al. 2006. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. Am J Ther, 13:192-7.
13. Cleophas TJ, Grabowsky I, Niemeyer MG, et al. 2001. Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr Ther Res, 62:451-61.
14. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. 1995. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/ NO-dependent mechanism. J Pharmacol Exp Ther, 274:1067-71.
15. Cockcroft JR, Wilkinson IB, Webb DJ. 1997. The Trevor Howell Lecture: age, arterial stiffness and the endothelium. Ageing, 26:53-60.
16. Cruickshank JM, Prichard BNC. 1987. Beta-blockers in clinical practice. Edinburgh: Churchill Livingstone.
17. Cruickshank K, Riste L, Anderson SG, et al. 2002. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. An integrated index of vascular function? Circulation, 106:2085-90.
18. Dawes M, Brett SE, Chowienczyk PJ, Mant TGK, et al. 1999. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. J Clin Pharmacol, 48:460-3.
19. De Cree J, Geukens H, Verhaegen H. 1991. Non-invasive cardiac haemodynamics of nebivolol. Clin Drug Investig, 3 (Suppl 1):25-30.
20. Dhakam Z, McEniery CM, Yasmin, et al. 2006. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens, 19:214-9.
21. Dreary AJ, Schumann AL, Murfet H, et al. 2002. Influence of drugs and gender on the arterial pulse wave and natiuretic peptide secretion in untreated patients with essential hypertension. Clin Sci, 103:493-9.
22. Erdogan D, Gullu H, Caliskan M, et al. 2007. Nebivolol improves coronary flow reserve in patients with idiopathic dilated Cardiomyopathy. Heart, 93:319-24.
23. Fallois JV, Faulhaber H-D. 2001. Nebivolol, a third generation beta-blocker: the current treatment of arterial hypertension. Praxis, 90:435-41.
24. Flather MD, Shibata MC, Coats AJ, et al. 2005. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 26:215-25.
25. Fogari R, Zoppi A, Lazzari P, et al. 1997. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive patients with type II diabetes. J Hum Hypertens, 11:753-7.
26. Gao Y, Nagao T, Bond RA, et al. 1991. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol, 17:964-9.
27. Kamp O, Sieswerda GT, Visser CA. 2003. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol, 92:344-8.
28. Kannel WB, Wilson PW, Zhang TJ. 1991. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J, 121:1268-73.
29. Kass DA. 2002. Age-related changes in venticular-arterial coupling: pathophysiologic implications. Heart Fail Rev, 7:51-62.
30. Kawaguchi M, Hay I, Fetics B, et al. 2003. Combined ventricular systolic arid arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation, 107:714-720.
31. Kelly R, Daley J, Avolio A, et al. 1989. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension, 14:14-21.
32. Kinlay S, Creager MA, Fukumoto M, et al. 2001. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension, 38:1049-53.
33. Lacourciere Y, Arnott W. 1994. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens, 8:283-8.
34. Lacourciere Y, Poirier L, Lefebvre J. 1992. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol, 32:660-6.
35. Laurent S, Boutouyrie P, Asmar R, et al. 2001. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension, 37:1236-41.
36. Lindholm LH, Carlberg B, Samuelsson O. 2005. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 366:1545-53.
37. Lombardo RM, Reina C, Abrignani MG, et al. 2006. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs, 6:259-63.
38. Mason RP. 2006. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich), 8:31-8.
39. Mason RP, Kalinowski L, Jacob RF, et al. 2005. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation, 112:3795-801.
40. Mazza A, Gil-Extremera B, Maldonato A, et al. 2002. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press, 11: 182-8.
41. McEniery CM, Schmitt M, Qasem A, et al. 2004. Nebivolol increases arterial distensibility in vivo. Hypertension, 44:305-10.
42. Meaume S, Benetos A, Henry OF, et al. 2001. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol, 21:2046-50.
43. Millar JA, Lever AF, Burke V. 1999. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens, 17:1065-72.
44. Mitchell GF, Moye LA, Braunwald E, et al. 1997. Sphygomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation, 96:4254-60.
45. Mitchell GF, Tardif JC, Arnold JM, et al. 2001. Pulsatile hemodynamics in congestive heart failure. Hypertension, 38:1433-9.
46. Moncada S. 1994. Nitric oxide. J Hypertens Suppl, 12:S35-S9.
47. Mottram PM, Haluska BA, Leano R, et al. 2005. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart, 91:1551-6.
48. NICE. 2006. Hypertension: Management of Hypertension in Adults in Primanny care - Partial update. NICE.
49. O'Rourke MF, Kelly RP, Avolio AP, et al. 1989. Effects of arterial dilator agents on central systolic pressure and on left ventricular hydraulic load. Am J Cardiol, 63:381-441.
50. Palatini P, Casiglia E, Julius S. 1999. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Int Med, 159:585-92.
51. Palmer RM, Ashton DS, Moncada S. 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 333:664-6.
52. Pedersen ME, Cockcroft JR. 2006. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep, 8:279-86.
53. Redfield MM, Jacobsen SJ, Borlaug BA, et al. 2005. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation, 112:2254-62.
54. Resnick LM, Lester MH. 2002. Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens, 15:1096-100.
55. Ritter JM. 2001. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol, 38 (Suppl 3):S13-S16.
56. Robertson JIS, Ball SG. 1994. Hypertension for the clinician. London: W.B. Saunders.
57. Schmitt M, Avolio A, Qasem A, et al. 2005. Basal NO locally modulates human iliac artery function in vivo. Hypertension, 46:227-31.
58. Shibata M, Flather M, Wang W. 2001. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Failure, 3:351-7.
59. Staessen J, Wang J-G, Thijs L. 2003. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. Hypertension, 21:1055-76.
60. Steiner SS, Friedhoff AJ, Wilson BL, et al. 1990. Antihypertensive therapy and quality of life: comparison of atenolol, enalapril and propanolol. J Hum Hypertens, 4:217-25.
61. Stoleru L, Wijns W, van Eyll C, et al. 1993. Effects of d-nebivolol and 1-nebivolol on left ventricular systolic and diastolic function: comparison with dl-nebivolol and atenolol. J Cardiovasc Pharmacol, 22:183-90.
62. Tzemos N, Lim PO, MacDonald TM. 2001. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation, 104:511-14.
63. Uhlir O, Fejifusa M, Havranek K. 1991. Nebivolol versus metoprolol in the treatment of hypertension. Clin Drug Investig, 3(Suppl 1): 107-10.
64. Van Bortel LM, Bulpitt CJ, Fici F. 2005. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens, 18:1060-6.
65. Van Bortel LMAB, Breed JGS, Joosten J, et al. 1993. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol, 21:856-62.
66. Van Bortel LMAB, de Boon JNJM, Kool MJ, et al. 1997. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol, 51:379-84.
67. Van Bortel LMAB, Kool MJ, Boudier HA, et al. 1995. Effects of antihypertensive agents on local arterial distensibility and compliance. Hypertension, 26:531-4.
68. Van Bortel LMAB, Van Baak MA. 1992. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther, 6:239-47.
69. Van de Water A, Janssens WJ, Van Nueten L, et al. 1988. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective beta1-adrenergic antagonist. J Cardiovasc Pharmacol, 11:552-63.
70. Van Merode T, Van Bortel LMAB, Smeets FA. 1989. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens, (Suppl 7):S262-S3.
71. Van Nueten L, De Cree J. 1998. Nebivolol: a comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Therap, 12:339-44.
72. Van Nueten L, Dupont AG, Vertommen C, et al. 1997a. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens, 11:139-44.
73. Van Nueten L, Lacourciere Y, Vyssoulis G, et al. 1998a. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind randomised comparative trial. Am J Therap, 5:237-43.
74. Van Nueten L, Schelling A, Vertommen C, et al. 1997b. Nebivolol versus enalapril in the treatment of essential hypertension:a double-blind randomised trial. J Hum Hypertens, 11:813-19.
75. Van Nueten L, Taylor FR, Robertson JI. 1998b. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens, 12:135-40.
76. Van Nueten L, Taylor FR, Robertson JIS. 1998c. Nebivolol versus atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens, 12:135-40.
77. van Popele NM, Mattace-Raso FU, Vliegenthart R, et al. 2006. Aortic stiffness is associated with atherosclerosis of the coronary arteries in older adults: the Rotterdam Study. J Hypertens, 24:2371-6.
78. WHO-ISH. 1999. Hypertension guidelines. J Hypertens, 17:151-83.
79. Wilkinson IB, Franklin SS, Cockcroft JR. 2004. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension, 44:112-6.
80. Wilkinson IB, McEniery CM, Cockcroft JR. 2006. Atenolol and cardiovascular risk: an issue close to the heart. Lancet, 367:627-9.
81. Wilkinson IB, Qasem A, McEniery CM, et al. 2002. Nitric oxide regulates local arterial distensibility in vivo. Circulation, 105:213-7.
82. Williams B, Lacy PS, Thom SM, et al. 2006. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113:1213-25.
83. Yambe M, Tomiyama H, Hirayama Y, et al. 2004. Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res, 27:625-31.